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Background: Previous findings suggested that bevacizumab might be able to improve response rate (RR) in colorectal cancer
patients with high lactic dehydrogenase (LDH) basal levels.
Methods:We conducted a phase II trial to prospectively ascertain whether bevacizumab in combination with FOLFIRI could have
an improved clinical activity in patients with high LDH serum levels. Primary end point of the study was RR; secondary end points
were median overall survival and median progression-free survival (mPFS).
Results: A total of 81 patients were enrolled. No difference in terms of ORR (39% vs 31% for low vs high LDH level stratum,
P¼ 0.78) and mPFS (14.16 vs 10.29 months, HR: 1.07, 95% CI: 0.51–2.24, P¼ 0.83) between the strata was observed, whereas overall
survival (OS) was significantly longer for patients with low LDH (24.85 vs 15.14 months, HR: 4.08, 95% CI: 1.14–14.61, P¼ 0.0004). In a
not-pre-planned exploratory analysis using different cut-off ranges for LDH, we observed RR up to 70%, with no improvement in
progression-free survival or OS.
Conclusions: The CENTRAL trial failed to demonstrate that high LDH levels were related to a significantly improved RR in patients
receiving first-line FOLFIRI and bevacizumab. The LDH serum levels should then no further be investigated as a predictive factor in
this setting.
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The introduction of different treatment options (Fakih, 2015) in
the therapeutic scenario of metastatic colorectal cancer (CRC)
patients (Aprile et al, 2015) led to a substantial improvement in
prognosis during the past few years. To date, however, no preferred
first-line therapy has been identified. On the one hand we can now
exclude from anti-EGFR treatment patients with putative refrac-
tory colorectal tumours (i.e., those harbouring a RAS mutant
status), but on the other hand we are still lacking any predictive
marker of response in this setting. Furthermore, although tumour-
driven angiogenesis is a key target for metastatic CRC, no effective
clinical or biological biomarker has been yet validated for patients
receiving antiangiogenic therapy (Giampieri et al, 2014). Most of
the data investigating molecular predictive factors in CRC patients
receiving bevacizumab in combination with chemotherapy
(Hurwitz et al, 2004; Saltz et al, 2008; Gonza´lez-Vacarezza et al,
2015; Pinto et al, 2016) suggested a potential role for the hypoxia-
induced angiogenesis model. The hypoxia-inducible factor 1-a has
a crucial function as transcription factor upregulating the
neoangiogenesis process and influencing the transcription of
several glycolytic enzymes such as lactic dehydrogenase (LDH)
(Maxwell et al, 2001). As a consequence high LDH levels might be
an indirect sign of activated tumour angiogenesis (Tas et al, 2001a;
Tas et al, 2001b; Faloppi et al, 2016). In fact, high LDH serum
levels besides indicating a diffuse metastatic involvement affecting
prognosis (Koukourakis et al, 2005; Wu et al, 2010), can also
indicate VEGF-A and VEGF receptor 1 overexpression (Azuma
et al, 2007).
We previously analysed the role of LDH pretreatment serum
levels in metastatic CRC patients receiving first-line chemotherapy
doublet with or without the addition of bevacizumab (Scartozzi
et al, 2012). Median progression-free survival (mPFS) in patients
treated without bevacizumab, stratified for high and low LDH
levels, was 4.2 vs 8 months (P¼ 0.0003), and median overall
survival (mOS) was 19.6 and 34.9, respectively (P¼ 0.0014). In the
bevacizumab-treated group, partial responses (PRs) were seen in
14 (58%) LDH-high and 8 (14%) LDH-low patients (P¼ 0.0243),
mPFS was 7.3 and 8.5 months, respectively (P¼ 0.2) and mOS was
22 and 26.6 months, respectively (P¼ 0.7).
On the basis of these findings we suggested that high LDH levels
were correlated with worse prognosis and that bevacizumab
seemed able to improve clinical outcome in this specific group of
patients that usually present with an adverse natural history. The
improved response rate (RR) also suggests a role for LDH as a
predictive marker. A prospective validation of these results was
lacking and might be relevant for the clinical practice.
PATIENTS AND METHODS
The CENTRAL trial was a prospective phase II non-randomised
clinical trial with a up-front biomarker stratification. Patients
treated with first-line FOLFIRI and bevacizumab were prospec-
tively stratified according to LDH serum levels. The aim of the trial
was to prospectively ascertain whether bevacizumab in combina-
tion with chemotherapy could have an improved clinical activity in
patients with high LDH serum levels compared to patients with
normal LDH serum levels. Primary end point was RR; secondary
end points were mPFS, mOS and toxicity profile.
All consecutive histologically proven metastatic CRC patients
receiving first-line chemotherapy with FOLFIRI and bevacizumab,
as per Italian label, were eligible for our study. All patients were
prospectively stratified according to LDH serum levels upon study
entry. The cut-off value for high vs low LDH serum levels was set at
1.2 ULN based on our previous report (Scartozzi et al, 2012).
Treatment was administered as follows: irinotecan 180mgm 2 IV
infusion on day 1; leucovorin 200mgm 2 IV followed by 5-
fluorouracil 400mgm 2 IV bolus and 5-fluorouracil 600mgm 2
IV continuous infusion over 22 h on days 1 and 2, every 2 weeks in
combination with bevacizumab 5mg kg 1 on IV infusion on day 1
every 2 weeks. Dose reductions and supportive care as for local
guidelines. Response rate was assessed every 12 weeks according to
the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
criteria. Treatment was administered until progression, patients’
withdrawal of consent and unacceptable toxicity. Toxicities were
evaluated according to National Cancer Institute-Common
Toxicity Criteria 4.0 at every chemotherapy cycle. All patients
receiving at least one cycle were considered evaluable for toxicity.
This study was performed in accordance with the study
protocol, the ethical principles stated in the Declaration of Helsinki
as well as those indicated in the International Conference on
Harmonization (ICH) Note for Guidance on Good Clinical
Practice (GCP; ICH E6, 1995), and all applicable regulatory
requirements. All patients had to sign a written informed consent
before study entry. Adequate information was given to eligible
patients by the principal investigator or co-investigators at each
participating centres and in accordance with local regulations.
Written informed consent to participate in the clinical study had to
be given before any study-related activities were carried out. The
declaration of informed consent was personally signed and dated
by the subject, and by the investigator/person designated by the
investigator to conduct the informed consent discussion.
Statistical considerations. To detect a difference in terms of RR
among patients with high LDH serum levels (estimated around 15–
20%) and patients with normal LDH serum levels (estimated
around 50–55%), assuming a probability alpha of 0.10 and beta of
0.10, required sample size was 80 patients.
Statistical analysis was performed with the MedCalc Statistical
Software version 14.10.2 (MedCalc Software bvba, Ostend,
Belgium; http://www.medcalc.org; 2014). For statistical analysis,
RR was defined as the proportion of patients who achieved a
complete response (CR) or PR according to the RECIST criteria,
overall survival (OS) was defined as the time interval between the
treatment start date and death, or last follow-up visit for patients
lost at follow-up, whereas progression-free survival (PFS) was
defined as the interval between the treatment start date and death,
first sign of clinical progression or last follow-up visit for patients
lost at follow-up. The association between categorical variables was
estimated by w2-test. Survival distribution was estimated by the
Kaplan–Meier method. Significant differences in probability of
survival between the strata were evaluated by log-rank test. A
significant level of 0.05 was chosen to assess the statistical
significance.
For exploratory analyses receiver-operating characteristic
(ROC) curve analysis was used to individuate the optimal LDH
cut-off value in our population.
RESULTS
Patients’ baseline characteristics. A total of 81 patients were
enrolled at 18 sites in Italy: 49 males and 32 females, median age
was 65 years (34–80); 80% (65/81) had Eastern Cooperative Group
Performance Status (ECOG PS) 0, whereas 20% (16/81) had ECOG
PS 1; 67% (54/81) had metastatic disease at diagnosis, whereas 33%
(27/81) had locally advanced disease at the time of diagnosis.
Seventy-five per cent (61 out of 81) and 25% (20 out of 81) had
colon and rectal primary tumours, respectively (Table 1).
Treatment outcome and safety. In the global population 9% of
the patients (7 out of 81) achieved CR, 30% (24 out of 81) PR, 43%
(35 out of 81) stable disease, 11% (9/81) experienced progressive
disease (PD) at 12 weeks, and 7% (6 out of 81) did not undergo
radiological evaluation (1 patient died for causes other than cancer,
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2 patients withdrew their consent after study enrolment, 1 patient
stopped treatment for unacceptable toxicity and 2 patients stopped
treatment for medical causes other than cancer). At 2-year follow-
up, 52 out of 81 (64%) patients enrolled in the study had
progressed and mPFS was 12.98 months (95% CI: 8.0–16.06); 24
out of 81 (30%) patients had died and mOS was 24.52 months
(95% CI:20.75–25.47). Most common grade 3–4 adverse events
reported were diarrhoea (11.4%), neutropenia (17%; febrile
neutropenia: 7%) and others 11%.
Stratification according to LDH levels. Among enrolled patients
47% (38 out of 81) had high LDH levels, whereas 43% (35 out of
81) had low LDH levels. In 8 patients (10%) LDH level was not
assessed at the time of study entry.
Primary end point. Overall RR in the high LDH level stratum and
in the low LDH level stratum was 39% (15 out of 38) vs 31% (11
out of 35) (P¼ 0.78).
Secondary end points. There was no difference in terms of PFS
between the two groups (mPFS 14.16 vs 10.29 months for low vs
high, HR: 1.07, 95% CI: 0.51–2.24, P¼ 0.83; Figure 1). On the
contrary, we observed a significantly longer median post-progres-
sion survival after first line (3.14 vs 17.4 months, HR: 2.61, 95% CI:
0.74–9.20, P¼ 0.004), and OS was significantly longer for patients
with low LDH vs those who had high LDH (mOS 24.85 vs 15.14,
HR: 4.08, 95% CI: 1.14–14.61, P¼ 0.0004; Figure 2).
Unplanned exploratory analysis according to different LDH cut-
off levels. The ROC curve analysis indicated that ULN 0.87 had
the best Youden index (0.34) with a sensitivity of 67% and a
specificity of 67% (Figure 3).
In all, 12 out of 17 patients (70%) with LDH serum levels
between ULN 0.87 and ULN 1 (17 out of 81, 21% of the global
population) showed a response to treatment (CR and PR).
However, this did not translate into a significantly different PFS
among patients showing LDH levels below ULN 0.87 vs
ULN 0.87–ULN 1 vs those showing LDH levels above
ULN 1 (mPFS 12.98 vs 15.21 vs 12.13 months, P¼ 0.87;
Figure 4). Patients with LDH-high serum levels (4ULN 1)
experienced a worse survival than patients with LDH serum levels
o0.87 ULN or patients with LDH between ULN 0.87 and
ULN 1 (mOS 24.52 vs 24.85 vs 15.14 months, P¼ 0.02; Figure 5).
DISCUSSION
Our trial failed to prospectively confirm that LDH serum levels
above ULN 1.2 were related to significantly improved RR in
metastatic colorectal patients receiving first-line treatment with
FOLFIRI and bevacizumab.
A selection bias deriving from factors such as tumour burden,
RAS/B-RAF status and site of primary metastatic involvement
(liver vs lung vs both vs others) might have confounded the impact
of high LDH levels as predictor of improved RR during
chemotherapy in combination with bevacizumab. In particular,
the relatively high number of patients experiencing CR during
treatment in our study was mainly dependant on the fraction of
patients (10 out of 81, 12%) with isolated small-lung metastases, a
subset of patients reportedly to have a particularly favourable
outcome. Furthermore, the reported mOS for the whole population
(24.5 months) was not completely in line with recent studies
suggesting more encouraging figures for this parameter. The mPFS
(12.98 months) was on the contrary comparable to available data
in similar case series (Stintzing et al, 2016; Bennouna et al, 2017).
Accordingly, to our findings a recently published meta-analysis (Li
et al, 2016) showed that high LDH levels might be related to an
adverse impact on OS, with a small positive predictive impact on
PFS. Similar results were also published by Silvestris et al (2015) in
metastatic CRC patients receiving first-line bevacizumab in
combination with FOLFIRI. On the one hand the authors of this
study confirmed that high LDH levels were related to a worse OS
and on the other hand they also suggested an OS improvement in
patients showing a decrease in LDH serum levels during treatment.
A recent analysis (Marmorino et al, 2017) indicated that high
LDH levels seemed more likely to predict a worse outcome in
patients receiving beyond-progression administration of bevacizu-
mab in combination with chemotherapy, thus suggesting a more
evident negative impact of LDH values on post-progression
survival, such as in our study.
Table 1. Patients and tumour baseline characteristics
Patients 81
Gender
Male 49
Female 32
Mean age (years) 62.86
Median age (range) 65 (34–80)
Performance status
0 80% (65 out of 81)
1 20% (16 out of 81)
Site of primary tumour
Sigma-colon 75% (61 out of 81)
Rectum 25% (20 out of 81)
Metastases (M)
0 33% (27 out of 81)
1 67% (54/81)
Site of metastasis
Liver 38
Liverþother 18
Lymph nodes 6
Lung 10
Other sites 9
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Figure 1. Median progression-free survival according to LDH levels.
Median progression-free survival (PFS) for patients receiving first-line
FOLFIRI and bevacizumab prospectively stratified according to LDH
low (blue line) or high (green line) serum levels. Median PFS was 14.16
vs 10.29 months for patients with low vs high LDH (HR: 1.07, 95% CI:
0.51–2.24, P¼ 0.83). A full colour version of this figure is available at
the British Journal of Cancer journal online.
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Participating centres contributed to patients’ enrolment blindly
(except for the coordinating centre) in accordance to the pre-
defined cut-off value. Therefore, we believe that the hypothesis of a
process of ‘selection’ of patients with an increased/decreased
likelihood of response based on their disease status, rather than
effectively on the LDH level, can be excluded.
The trial might have failed its primary end point as a
consequence of a sub-optimal LDH serum levels’ cut-off value
choice (for LDH: to solve this issue, we compared our results to
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Figure 2. Median overall survival according to LDH levels. Median
overall survival (OS) for patients receiving first-line FOLFIRI and
bevacizumab prospectively stratified according to LDH low (blue line)
or high (green line) serum levels. Median OS was 24.85 vs 15.14 for
patients with low LDH vs high LDH (HR: 4.08, 95% CI: 1.14–14.61,
P¼0.0004). A full colour version of this figure is available at the British
Journal of Cancer journal online.
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Figure 4. Median PFS according to different levels of LDH. Median
PFS according to three different levels of LDH: lower (green line) vs
intermediate (blue line) vs upper (orange line). Progression-free survival
was 12.98 for lower vs 15.21 for intermediate vs 12.13 for upper LDH
(P¼ 0.87). A full colour version of this figure is available at the British
Journal of Cancer journal online.
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Figure 5. Median OS according to different levels of LDH. Median OS
according to three different levels of LDH: lower (green line) vs
intermediate (blue line) vs upper (orange line). Overall survival was
24.52 and 24.58 months for patients with lower levels of LDH and
intermediate values of LDH vs 15.14 months for patients with LDH
greater than ULN1 (P¼ 0.02). A full colour version of this figure is
available at the British Journal of Cancer journal online.
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Figure 3. Receiver-operating characteristics analysis based on
pretreatment LDH serum levels. Receiver-operating characteristic
(ROC) analysis based on pretreatment LDH serum levels results with OS
as end point. In this model, sensitivity was 66.7% (95% CI: 40.7–82.8)
and specificity was 67.3% (95% CI: 71.9–93.1). The area under the
curve was 0.610, P¼0.0942. A full colour version of this figure is
available at the British Journal of Cancer journal online.
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other trials that tried to assess the role of high LDH and potential
efficacy of antiangiogenic drugs).
In the CONFIRM-1 (Hecht et al, 2011) and CONFIRM-2 (Van
Cutsem et al, 2011) trials, although the addition of PTK/ZK to
first- and second-line FOLFOX failed to improve OS and PFS in
metastatic CRC patients, patients with levels of LDH above
ULN 1.5 also had improved survival outcomes.
In our unplanned exploratory analysis we observed an
impressively high RR in patients showing LDH serum levels
between ULN 0.87 and ULN 1. In addition, when we
performed a ROC curve analysis for PD in this population and
used ULN 1.2 as cut-off, sensitivity for PD increased. Taken
together these findings might suggest that the role of LDH as
potential predictive marker is likely to be offset by its prognostic
function particularly when high levels of LDH are observed.
In a previously published analysis from our group (Del Prete
et al, 2015) treatment outcome was adversely affected by high LDH
levels in patients receiving third- and forth-line regorafenib for
metastatic CRC, thus suggesting a potential negative prognostic
effect in heavily pretreated patients as well. This seems in line with
the results of our study in terms of OS, suggesting once again a
much stronger role of LDH as negative prognostic factor rather
than as positive predictive factor.
Finally, different LDH isoforms might have different functions in
this setting. Serum LDH is the result of the sum of circulating levels
of at least five different isoforms. Although LDH is an enzyme that
catalyses the same chemical reaction of Hþ release from lactic acid
molecule, not all isoforms are inducible as a result of a hypoxic insult
and not all isoforms catalyse the reaction similarly. These considera-
tions may partly explain some of the results of our analysis. We can
hypothesise that for patients with relevant tumour burden but with
an adequate tumour blood (and then oxygen) supply, high LDH
levels are not dependent on hypoxia but may better reflect the overall
tumour burden with consequential prognostic implications. On this
basis, it would be interesting to verify whether LDH-5 isoform levels,
which have been more closely linked to hypoxia, are related to
patients outcome during antiangiogenic treatment. Intriguingly data
from the CONFIRMS trials suggested that LDH-5 expression was
significantly related to worse prognosis, but this prognostic effect was
reverted in patients receiving the antiangiogenic drug vatalanib
(Koukourakis et al, 2011).
The present prospective study failed to confirm retrospective
data suggesting that LDH serum levels might have a predictive role
during bevacizumab treatment in metastatic CRC patients.
As a consequence LDH serum levels should not be further
investigated as a predictive factor.
On the basis of our findings and those from other authors
we confirm the strong correlation between high LDH serum
levels and prognosis in this group of patients. We then suggest
that LDH serum levels besides representing a potentially
relevant stratification factor for clinical trials for metastatic
CRC patients, should also be part of the basic clinical assessment
in the clinical practice with the aim to better define overall
prognosis.
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